Therapeutic Goods Amendment (Repeal of Ministerial responsibility for approval of RU486) Act 2006

Overview

The Therapeutic Goods Amendment (Repeal of Ministerial responsibility for approval of RU486) Act 2006 was enacted to address the need for a change in the responsibility for the approval of RU486, a pharmaceutical product, from the Minister to the Therapeutic Goods Administration. The Act was introduced to streamline the approval process and enhance the efficiency of regulatory oversight. It was assented to on 3 March 2006 by the Parliament of Australia, with the clear purpose of transferring the approval authority from the Minister to the Therapeutic Goods Administration, as stated in the Act. This legislative change was intended to ensure that the regulatory framework for therapeutic goods in Australia is both effective and up-to-date.

Scope and Application

The Therapeutic Goods Amendment (Repeal of Ministerial responsibility for approval of RU486) Act 2006 pertains specifically to the approval process of RU486, a therapeutic good used for medical termination of pregnancy. The Act applies to the Minister of Health and the Therapeutic Goods Administration, transferring the responsibility of approving RU486 from the Minister to the Therapeutic Goods Administration. This legislation has a Commonwealth reach, impacting the approval process of therapeutic goods across Australia. The Act is designed to streamline and formalise the approval process by removing the ministerial responsibility and placing it with a dedicated regulatory body. The Act does not explicitly detail exclusions or exemptions, but it focuses solely on the specific therapeutic good RU486, indicating its targeted application. The scope of the Act is further defined and potentially extended through its Schedule, which amends the Therapeutic Goods Act 1989 by repealing specific sections and definitions related to RU486.

Key Provisions

The Therapeutic Goods Amendment (Repeal of Ministerial Responsibility for Approval of RU486) Act 2006 (No. 5, 2006) fundamentally changes the framework under which RU486, also known as mifepristone, is approved in Australia. The Act repeals certain provisions in the Therapeutic Goods Act 1989, transferring the responsibility for the approval of RU486 from the Minister to the Therapeutic Goods Administration (TGA). Specifically, Section 1(1) of Schedule 1 repeals the definition of "restricted goods" under Subsection 3(1), while Section 1(2) repeals Sections 6AA, 6AB, and 23AA, and Subsection 57(9) of the Therapeutic Goods Act 1989. These repealed sections previously outlined the ministerial approval process for RU486. The Act imposes obligations on the TGA to assume responsibility for the approval of RU486, ensuring that the drug meets all necessary safety, efficacy, and quality standards. This transition necessitates that the TGA implement stringent evaluation and monitoring processes to oversee the approval and ongoing regulation of RU486, ensuring public safety and compliance with legislative requirements. The TGA must now maintain detailed records and provide transparency in its approval processes, ensuring all stakeholders are informed of the decisions and criteria used. Failure to comply with the provisions of the Therapeutic Goods Amendment Act or the decisions made by the TGA can lead to significant legal consequences. While the Act does not explicitly state penalties, breaches of the Therapeutic Goods Act 1989, now governed by the TGA, can result in substantial fines and, in severe cases, imprisonment. The penalties for contravening the regulations set by the TGA can include fines of up to $22,000 for individuals and $110,000 for corporations, alongside potential imprisonment terms. Additionally, ongoing non-compliance can lead to repeat offences, escalating the penalties imposed. These provisions underscore the importance of adherence to the regulatory framework established by the Act.